DIAGNOSTIC VALUE OF ANTI-MULLERIAN HORMONE AS A BIOMARKER FOR POLYCYSTIC OVARY SYNDROME: A META-ANALYSIS UPDATE

被引:12
作者
Zhao, Yang [2 ]
Zhao, Yinlong [3 ]
Wang, Chunpeng [4 ]
Liang, Zhenzhen [5 ]
Liu, Xin [1 ]
机构
[1] Jilin Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Changchun, Jilin, Peoples R China
[2] Jilin Univ, Sch Clin Med, Changchun, Jilin, Peoples R China
[3] Jilin Univ, Hosp 2, Dept Nucl Med, Changchun, Jilin, Peoples R China
[4] Northeast Normal Univ, Sch Math & Stat, Changchun, Jilin, Peoples R China
[5] Jilin Univ, NHC Key Lab Radiobiol, Changchun, Jilin, Peoples R China
关键词
SERUM; CONSENSUS; INFERTILITY; DEFINITION; ULTRASOUND; CRITERIA; WOMEN; AMH;
D O I
10.4158/EP-2019-0098
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: A previous meta-analysis carried out on the predictive ability of anti-Miillerian hormone (AMH) for polycystic ovary syndrome (PCOS) showed that independent AMH may be a useful initial diagnostic test for PCOS. The aims of this study were to update the meta-analysis and to evaluate the diagnostic efficacy of AMH when it replaces polycystic ovary morphology (PCOM) in the Rotterdam criteria. Methods: Two independent reviewers searched PubMed, Cochrane Library, and the Web of Science databases systematically to identify relevant articles by using the key words "anti-Mtillerian hormone" and "polycystic ovary syndrome." The deadline for manuscript inclusion was July 31, 2018. A random effects model was used and subgroup analysis and meta regression were performed to identify possible sources of heterogeneity. The methodologic quality of each study was assessed by QUADAS-2 and funnel plot asymmetry test. Results: According to the inclusion criteria, 29 studies were included in this meta-analysis. The pooled sensitivity, specificity, and diagnostic odds ratio (DOR) for AMH alone detecting PCOS were 0.76 (95% confidence interval [CI] 0.71 to 0.81), 0.86 (95% CI 0.82 to 0.90) and 20 (95% CI 12 to 33), respectively. When AMI-1 replaces polycystic ovary morphology (PCOM) for the diagnosis of PCOS, the pooled sensitivity, specificity, and DOR rose to 0.93 (95% CI 0.89 to 0.96), 0.99 (95% CI 0.95 to 1.00), and 1,634 (95% CI 217 to 12,324), respectively. The area under the summary receiver-operating characteristic curve for AMH alone and for AMH replacing PCOM detecting PCOS were 0.88 (95% CI 0.85 to 0.91) and 0.97 (95% CI 0.95 to 0.98), respectively, which was found to be significantly different (Z = 4.89, P<.01). Conclusion: When AMH replaces PCOM in the Rotterdam criteria, the diagnostic efficacy for polycystic ovary syndrome is better.
引用
收藏
页码:1056 / 1066
页数:11
相关论文
共 50 条
[41]   Mullerian-Inhibiting Substance/Anti-Mullerian Hormone as a Predictor of Preterm Birth in Polycystic Ovary Syndrome [J].
Hsu, Jennifer Y. ;
James, Kaitlyn E. ;
Bormann, Charles L. ;
Donahoe, Patricia K. ;
Pepin, David ;
Sabatini, Mary E. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (11) :4187-4196
[42]   Salivary and serum androgens with anti-Mullerian hormone measurement for the diagnosis of polycystic ovary syndrome [J].
Sathyapalan, Thozhukat ;
Al-Qaissi, Ahmed ;
Kilpatrick, Eric S. ;
Dargham, Soha R. ;
Keevil, Brian ;
Atkin, Stephen L. .
SCIENTIFIC REPORTS, 2018, 8
[43]   Correlation between anti-mullerian hormone with insulin resistance in polycystic ovarian syndrome: a systematic review and meta-analysis [J].
Muslim, Mohd Zakwan Md ;
Jelani, Aniza Mohammed ;
Shafii, Noorazliyana ;
Yaacob, Najib Majdi ;
Soh, Noor Azlin Azraini Che ;
Ibrahim, Hanim Afzan .
JOURNAL OF OVARIAN RESEARCH, 2024, 17 (01)
[44]   Use of the serum anti-Mullerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome [J].
Fraissinet, Alice ;
Robin, Geoffroy ;
Pigny, Pascal ;
Lefebvre, Tiphaine ;
Catteau-Jonard, Sophie ;
Dewailly, Didier .
HUMAN REPRODUCTION, 2017, 32 (08) :1716-1722
[45]   Substituting serum anti-Mullerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study [J].
Bell, Robin J. ;
Islam, Rakibul M. ;
Skiba, Marina A. ;
Herbert, Dilinie ;
Garcia, Alejandra Martinez ;
Davis, Susan R. .
HUMAN REPRODUCTION, 2022, 37 (01) :109-118
[46]   Anti-Mullerian hormone and antral follicle count for prediction of ovarian stimulation response in polycystic ovary syndrome [J].
El-Mazny, Akmal ;
Abou-Salem, Nermeen .
GYNECOLOGICAL ENDOCRINOLOGY, 2013, 29 (09) :826-829
[47]   Dysregulation of the Anti-Mullerian Hormone System by Steroids in Women With Polycystic Ovary Syndrome [J].
Pierre, Alice ;
Taieb, Joelle ;
Giton, Frank ;
Grynberg, Michael ;
Touleimat, Salma ;
El Hachem, Hady ;
Fanchin, Renato ;
Monniaux, Danielle ;
Cohen-Tannoudji, Joelle ;
di Clemente, Nathalie ;
Racine, Chrystele .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (11) :3970-3978
[48]   Anti-Mullerian hormone (AMH) as a useful marker in diagnosis of polycystic ovary syndrome [J].
Leonte, Laura ;
Coculescu, M. ;
Radian, S. ;
Fica, Simona ;
Caragheorgheopol, Andra ;
Marinescu, B. ;
Bohaltea, L. C. ;
Grigorescu, F. .
ACTA ENDOCRINOLOGICA-BUCHAREST, 2007, 3 (01) :1-11
[49]   Anti-Mullerian Hormone and Polycystic Ovary Syndrome in Women and Its Male Equivalent [J].
di Clemente, Nathalie ;
Racine, Chrystele ;
Rey, Rodolfo A. .
BIOMEDICINES, 2022, 10 (10)
[50]   Expression of anti-Mullerian hormone in letrozole rat model of polycystic ovary syndrome [J].
Du, Dan-Feng ;
Li, Xue-Lian ;
Fang, Fang ;
Du, Mei-Rong .
GYNECOLOGICAL ENDOCRINOLOGY, 2014, 30 (12) :885-889